{
    "symbol": "OCGN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-28 13:39:07",
    "content": " Regarding our injectable COVID-19 vaccine already in development, co-vaccine, we successfully completed enrollment for our COVAXIN Phase II/III immune-bridging and broadening clinical trial in December 2022 and reported top line data in January 2023. For the full year ended December 31, 2022, research and development expense was $49.8 million compared to $35.1 million for the year ended December 31, 2021, with the increase primarily driven by the advancement of our product candidates into clinical trials."
}